EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Toad venom bufadienolides and bufotoxins: An updated review

Akmal M Asrorov iD, Muzaffar Kayumov, Nurkhodja Mukhamedov, Ansor Yashinov, Ziyoda Mirakhmetova, Yongzhuo Huang, Abulimiti Yili, Haji Akber Aisa, Mugrajitdin Tashmukhamedov, Shavkat Salikhov, Sharafitdin Mirzaakhmedov

Drug Development Research · 2023

DOI: 10.1002/ddr.22072 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2023. Verfasst von Akmal M Asrorov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, Uzbekistan. Hauptthemen laut MEDLINE: Bufanolides, Antineoplastic Agents, Amphibian Venoms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: Ministry of Innovative Development of the Republic of Uzbekistan, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bufadienolides, naturally found in toad venoms having steroid‐like structures, reveal antiproliferative effects at low doses. However, their application as anticancer drugs is strongly prevented by their Na + /K + ‐ATPase binding activities. Although several kinds of research were dedicated to moderating their Na + /K + ‐ATPase binding activity, still deeper fundamental knowledge is required to bring these findings into medical practice. In this work, we reviewed data related to anticancer activity of bufadienolides such as bufalin, arenobufagin, bufotalin, gamabufotalin, cinobufotalin, and cinobufagin and their derivatives. Bufotoxins, derivatives of bufadienolides containing polar molecules mainly belonging to argininyl residues, are reviewed as well. The established structures of bufotoxins have been compiled into a one‐page figure to review their structures. We also highlighted advances in the structure‐modification of the structure of compounds in this class. Drug delivery approaches to target these compounds to tumor cells were discussed in one section. The issues related to extraction, identification, and quantification are separated into another section.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BufanolidesAntineoplastic AgentsAmphibian VenomsAdenosine Triphosphatases

Stichwörter der Autor:innen

arenobufaginbufadienolidesbufalinbufotalincinobufagincinobufotalingamabufotalin

Substanzen

bufotoxinBufanolidesAntineoplastic AgentsAmphibian VenomsAdenosine Triphosphatases

Autor:innen und Institutionen

  • Institute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, Uzbekistan.
  • Department of Natural Substances Chemistry, National University of Uzbekistan, Tashkent, Uzbekistan.
  • Shanghai Institute of Materia Medica, CAS, Shanghai, China.
  • University of Chinese Academy of Sciences (UCAS), Beijing, China.
  • Xinjiang Technical Institute of Physics and Chemistry, CAS, Urumqi, China.

ORCID-Profile: Akmal M Asrorov

Förderung

  • Ministry of Innovative Development of the Republic of Uzbekistan
  • Chinese Academy of Sciences

Zitieren

APA

Asrorov, A. M., Kayumov, M., Mukhamedov, N., Yashinov, A., Mirakhmetova, Z., Huang, Y., Yili, A., Aisa, H. A., Tashmukhamedov, M., Salikhov, S., & Mirzaakhmedov, S. (2023). Toad venom bufadienolides and bufotoxins: An updated review. Drug Development Research. https://doi.org/10.1002/ddr.22072

Vancouver

Asrorov AM, Kayumov M, Mukhamedov N, Yashinov A, Mirakhmetova Z, Huang Y, et al. Toad venom bufadienolides and bufotoxins: An updated review. Drug Development Research. 2023. doi:10.1002/ddr.22072

BibTeX
@article{Asrorov2023,
  author = {Asrorov, Akmal M and Kayumov, Muzaffar and Mukhamedov, Nurkhodja and Yashinov, Ansor and Mirakhmetova, Ziyoda and Huang, Yongzhuo and Yili, Abulimiti and Aisa, Haji Akber and Tashmukhamedov, Mugrajitdin and Salikhov, Shavkat and Mirzaakhmedov, Sharafitdin},
  title = {Toad venom bufadienolides and bufotoxins: An updated review},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22072}
}
Kostenlos starten →